First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Cancer center, Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital, Guangzhou, Guangdong, China.
PLoS One. 2020 Dec 17;15(12):e0243164. doi: 10.1371/journal.pone.0243164. eCollection 2020.
BACKGROUND: Primary acinar cell carcinoma (ACC) is a rare exocrine tumor of the pancreas with unclear clinical characteristics. Our goal was to determine the incidence and update the clinical characteristics and outcomes of ACC. METHODS: Through the Surveillance, Epidemiology, and End Results (SEER) database, we identified 252 patients with the latest diagnosis of ACC (2004-2016). The age-adjusted incidence (AAI) was calculated using the SEER*Stat Software version 8.3.6. The Kaplan-Meier method was used to draw survival curves and differences among them were compared by the log-rank test. Cox proportional hazards models were used to evaluate factors that had independent predictive effects on the overall survival. RESULTS: The AAI of pancreatic ACC was on the rise with the mean age at diagnosis of 63.79±14.79 years. Most patients (15.9%) had poorer differentiated tumors. The patients presented with distant stage were 54.4% compared with 53.1% between 1988 and 2003. The 1-, 2-, and 5-years survival rates for pancreatic ACC patients were 53.5%, 34.6%,17.5%, respectively (compared with 78.5%, 67.0%, and 42.8%, between 1988 and 2003). The multivariate COX analysis showed that the patient's age, surgery, chemotherapy, and summary stage, but not marital status were independent prognosis factors for ACC. CONCLUSIONS: Pancreatic ACC is a highly malignant tumor with an increasing incidence in recent years. The rate of distant metastasis is increasing and the survival rate is worse than in the past, suggesting that it may require more aggressive treatment and follow-up. Surgery, radiotherapy, and chemotherapy are all effective treatments, but prospective studies are still needed to verify them.
背景:原发性腺泡细胞癌(ACC)是一种罕见的胰腺外分泌肿瘤,其临床特征尚不清楚。我们的目标是确定 ACC 的发病率,并更新其临床特征和结局。
方法:通过监测、流行病学和最终结果(SEER)数据库,我们确定了 252 名最近被诊断为 ACC(2004-2016 年)的患者。使用 SEER*Stat 软件版本 8.3.6 计算年龄调整发病率(AAI)。采用 Kaplan-Meier 法绘制生存曲线,用对数秩检验比较差异。采用 Cox 比例风险模型评估对总生存有独立预测影响的因素。
结果:胰腺 ACC 的 AAI 呈上升趋势,平均诊断年龄为 63.79±14.79 岁。大多数患者(15.9%)肿瘤分化程度较差。远处转移患者占 54.4%,而 1988 年至 2003 年为 53.1%。胰腺 ACC 患者的 1、2 和 5 年生存率分别为 53.5%、34.6%和 17.5%(1988 年至 2003 年分别为 78.5%、67.0%和 42.8%)。多变量 COX 分析表明,患者的年龄、手术、化疗和总结分期,但不是婚姻状况,是 ACC 的独立预后因素。
结论:胰腺 ACC 是一种高度恶性肿瘤,近年来发病率呈上升趋势。远处转移率呈上升趋势,生存率较以往更差,提示可能需要更积极的治疗和随访。手术、放疗和化疗均为有效治疗方法,但仍需前瞻性研究加以验证。
J Stomatol Oral Maxillofac Surg. 2024-9
Thorac Cancer. 2021-9
J Gastrointest Cancer. 2025-4-23
Cancer Imaging. 2025-3-21
Cancer Treat Res. 2024
Ther Adv Med Oncol. 2024-7-26
J Cancer Res Clin Oncol. 2024-7-13
J Cancer Metastasis Treat. 2023
World J Gastroenterol. 2022-10-28
Arch Pathol Lab Med. 2020-7-1
Cancer Biol Ther. 2019-4-19
HPB (Oxford). 2018-12-2
BMC Cancer. 2018-11-8
World J Gastroenterol. 2017-12-7